Swiss National Bank Acquires 7,900 Shares of Arvinas, Inc. (NASDAQ:ARVN)

Swiss National Bank lifted its holdings in Arvinas, Inc. (NASDAQ:ARVN) by 11.2% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 78,600 shares of the company’s stock after acquiring an additional 7,900 shares during the quarter. Swiss National Bank’s holdings in Arvinas were worth $6,052,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the company. BlackRock Inc. lifted its holdings in shares of Arvinas by 6.6% in the 1st quarter. BlackRock Inc. now owns 3,001,264 shares of the company’s stock worth $198,384,000 after acquiring an additional 185,517 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Arvinas by 6.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,386,455 shares of the company’s stock worth $157,745,000 after acquiring an additional 141,006 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Arvinas by 7.3% in the 1st quarter. JPMorgan Chase & Co. now owns 1,730,985 shares of the company’s stock worth $114,418,000 after acquiring an additional 118,054 shares during the last quarter. Point72 Asset Management L.P. raised its holdings in Arvinas by 125.6% during the 1st quarter. Point72 Asset Management L.P. now owns 1,128,100 shares of the company’s stock valued at $74,567,000 after buying an additional 628,100 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in Arvinas by 15.1% during the 1st quarter. Geode Capital Management LLC now owns 593,972 shares of the company’s stock valued at $39,261,000 after buying an additional 77,854 shares during the last quarter. Hedge funds and other institutional investors own 92.92% of the company’s stock.

NASDAQ:ARVN opened at $94.20 on Friday. The firm’s 50-day moving average price is $88.95 and its 200-day moving average price is $76.68. The company has a market capitalization of $4.63 billion, a PE ratio of -25.81 and a beta of 1.98. Arvinas, Inc. has a 1-year low of $19.68 and a 1-year high of $108.46.

Arvinas (NASDAQ:ARVN) last released its earnings results on Wednesday, August 4th. The company reported ($1.03) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.86) by ($0.17). The business had revenue of $5.54 million during the quarter, compared to analysts’ expectations of $5.39 million. Arvinas had a negative return on equity of 31.99% and a negative net margin of 782.95%. As a group, analysts expect that Arvinas, Inc. will post 1.12 EPS for the current fiscal year.

ARVN has been the subject of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $135.00 price target (up from $100.00) on shares of Arvinas in a report on Friday, July 23rd. Zacks Investment Research upgraded shares of Arvinas from a “hold” rating to a “buy” rating and set a $113.00 price target for the company in a report on Monday, August 2nd. UBS Group initiated coverage on shares of Arvinas in a report on Thursday, May 20th. They set a “buy” rating and a $123.00 price target for the company. Bank of America initiated coverage on shares of Arvinas in a report on Thursday, September 9th. They set a “buy” rating and a $110.00 price target for the company. Finally, BMO Capital Markets upped their price target on shares of Arvinas from $101.00 to $111.00 and gave the company an “outperform” rating in a report on Friday, July 23rd. Fifteen investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $128.81.

In related news, Director Bradley Albert Margus sold 20,000 shares of the stock in a transaction dated Wednesday, August 25th. The shares were sold at an average price of $85.00, for a total transaction of $1,700,000.00. Following the sale, the director now directly owns 59,463 shares of the company’s stock, valued at approximately $5,054,355. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO John G. Houston sold 45,922 shares of the stock in a transaction dated Monday, August 2nd. The shares were sold at an average price of $97.83, for a total transaction of $4,492,549.26. Following the sale, the chief executive officer now directly owns 873,565 shares in the company, valued at $85,460,863.95. The disclosure for this sale can be found here. Insiders sold a total of 135,355 shares of company stock worth $12,294,800 over the last ninety days. Insiders own 6.45% of the company’s stock.

Arvinas Company Profile

Arvinas, Inc is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer.

Read More: What is a Reverse Stock Split?

Want to see what other hedge funds are holding ARVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arvinas, Inc. (NASDAQ:ARVN).

Institutional Ownership by Quarter for Arvinas (NASDAQ:ARVN)

Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.